China Pharma Holdings (CPHI) Cash & Equivalents (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Cash & Equivalents came in at $168474.0 in Q1 2026, down 59.18% YoY from $412688.0 in Q1 2025, and down 51.18% on a QoQ basis from $345112.0 in Q4 2025.
China Pharma Holdings (CPHI) Cash & Equivalents (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Cash & Equivalents data on file, last reported at $168474.0 in Q1 2026.
- Quarterly Cash & Equivalents fell 59.18% year-over-year to $168474.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168474.0 (down 59.18% YoY) and the FY2025 annual result came in at $345112.0, down 44.95% from the prior year.
- Cash & Equivalents slipped to $168474.0 in Q1 2026, from $345112.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $3.7 million in Q1 2022 to a low of $168474.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $838881.0 in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 594.97% — and 2023, when it slumped 68.59%.
- Tracing CPHI's Cash & Equivalents over 5 years: stood at $2.0 million in 2022, then fell by 29.86% to $1.4 million in 2023, then slumped by 55.97% to $626879.0 in 2024, then slumped by 44.95% to $345112.0 in 2025, then plunged by 51.18% to $168474.0 in 2026.
- The last three Cash & Equivalents figures came in at $168474.0 (Q1 2026), $345112.0 (Q4 2025), and $267625.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 164.00 Mn |
| 10 | China Pharma Holdings | 41.38 Mn | 41.08 Mn | 83,566.00 | 304,874.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 168,474.00 |
| Dec 31, 2025 | 345,112.00 |
| Sep 30, 2025 | 267,625.00 |
| Jun 30, 2025 | 625,032.00 |
| Mar 31, 2025 | 412,688.00 |
| Dec 31, 2024 | 626,879.00 |
| Sep 30, 2024 | 718,691.00 |
| Jun 30, 2024 | 739,337.00 |
| Mar 31, 2024 | 838,881.00 |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 901,910.00 |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.20 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 4.86 Mn |
| Sep 30, 2021 | 500,000.00 |
| Jun 30, 2021 | 1.80 Mn |